Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Payables (2023 - 2025)

Zhengye Biotechnology Holding has reported Payables over the past 3 years, most recently at $9.2 million for Q4 2025.

  • Quarterly Payables fell 17.15% to $9.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.2 million through Dec 2025, down 17.15% year-over-year, with the annual reading at $9.1 million for FY2025, 16.9% down from the prior year.
  • Payables was $9.2 million for Q4 2025 at Zhengye Biotechnology Holding, down from $11.2 million in the prior quarter.
  • Over five years, Payables peaked at $13.4 million in Q4 2023 and troughed at $9.2 million in Q4 2025.
  • The 3-year median for Payables is $11.2 million (2024), against an average of $11.3 million.
  • Year-over-year, Payables decreased 16.71% in 2024 and then fell 17.15% in 2025.
  • A 3-year view of Payables shows it stood at $13.4 million in 2023, then dropped by 16.71% to $11.1 million in 2024, then fell by 17.15% to $9.2 million in 2025.
  • Per Business Quant, the three most recent readings for ZYBT's Payables are $9.2 million (Q4 2025), $11.2 million (Q2 2025), and $11.1 million (Q4 2024).